FDA Approval of Abraxane Sets Stage for Competition Between Taxane Drugs. Abraxane a Nanotechnology Drug? Sponsor Says Yes, FDA Says.
Also in This 8-page Issue: NCI Seeks $6.17 Billion in “Bypass” Budget Request, But Faces Shortfall In Its Actual Budget.
NCI Names 15 to Director’s Consumer Liaison Group.
SAIC-Frederick Makes Awards To Proteomics Research Teams.
Latest State Cancer Statistics Released.
Smokers May Get Cessation Help From Medicare.
Funding Opportunities Listed.
Trending Stories
- Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives - Michael Caputo appointed to President’s Cancer Panel
The cancer survivor and political operative says his appointment signals Trump’s interest in cancer, survivorship - The Galleri MCD vote: What FDA asked its advisors to ignore
- From “default dead” to living the future of cancer care
As founding CEO of GitLab, I went “founder mode” on my osteosarcoma - FDA advisory committee votes in favor of Galleri approval, but calls for removal of “early” detection claims
Clinical benefit will not be considered for approval, FDA says - The Directors: Two Gulf Coast cancer center directors on why NCI designation matters—and why they want it
Lucio Miele and Raghu Kalluri: Science and technology have changed what an aspiring cancer center must accomplish
